ライフサイエンスコーパス: metastatic lesion

1 pectrum of resistance mutations present in a metastatic lesion.

2 te mutation appeared to arise de novo in the metastatic lesion.

3 and the presence or absence of a measurable metastatic lesion.

4 ther the chest tumor itself was a primary or metastatic lesion.

5 as used to compare atypical haemangiomas and metastatic lesions.

6 This pattern is further enhanced in metastatic lesions.

7 s describing the growth of primary tumors or metastatic lesions.

8 oRNA is significantly decreased in the brain metastatic lesions.

9 e growth of the primary tumor or the size of metastatic lesions.

10 stasis leading to the formation of focal pre-metastatic lesions.

11 biopsies of 73 primary breast cancers and 19 metastatic lesions.

12 and in situ characterization of primary and metastatic lesions.

13 aromatase availability in primary tumors and metastatic lesions.

14 n sites where they extravasate and establish metastatic lesions.

15 ssing osteosarcoma, and particularly for its metastatic lesions.

16 itates localization of the primary tumor and metastatic lesions.

17 rowth of primary tumors and the formation of metastatic lesions.

18 ors confer the capability of tumor growth at metastatic lesions.

19 erapeutic effects on both primary tumors and metastatic lesions.

20 odstream before the appearance of detectable metastatic lesions.

21 in the management of patients with multiple metastatic lesions.

22 effect of drugs on suppressing initiation of metastatic lesions.

23 relief at the site of primary tumor or from metastatic lesions.

24 rodeoxyglucose at detecting non-glucose-avid metastatic lesions.

25 confirmed folate uptake in both primary and metastatic lesions.

26 r primary tumor inflammation and early stage metastatic lesions.

27 s significantly elevated in both primary and metastatic lesions.

28 tases (superscan) to recognizable individual metastatic lesions.

29 e localization of panitumumab at primary and metastatic lesions.

30 genetic hallmark enriched in prostate cancer metastatic lesions.

31 ocal uptake of (131)I-GMIB-anti-HER2-VHH1 in metastatic lesions.

32 lls and continuously associates with growing metastatic lesions.

33 the primary tumor and/or in detecting small metastatic lesions.

34 8)F-FDG or (18)F-FLT uptake when focusing on metastatic lesions.

35 ue to hypersecretion of biogenic amines from metastatic lesions.

36 ic melanoma cell lines and human tissue from metastatic lesions.

37 n of clear cell RCC as the primary tumor for metastatic lesions.

38 nd slowed tumor progression and formation of metastatic lesions.

39 between atypical haemangiomas and malignant metastatic lesions.

40 tic melanoma cell lines and in patients with metastatic lesions.

41 ession, only at the invasive front of larger metastatic lesions.

42 areas of the body in patients with multiple metastatic lesions.

43 n is decreased in primary tumors and lost in metastatic lesions.

44 ) in poorly differentiated primary tumors or metastatic lesions.

45 Twenty-nine of 30 patients had metastatic lesions.

46 e in T2 sequences, mimicking the findings of metastatic lesions.

47 nd in particular, extensive staining of bone metastatic lesions.

48 may promote progression of breast tumors to metastatic lesions.

49 t sites where they extravasate and establish metastatic lesions.

50 ique could elucidate the tissue of origin of metastatic lesions.

51 ctive Smad signaling in human and mouse bone-metastatic lesions.

52 cell growth, angiogenesis and development of metastatic lesions.

53 s, including differences between primary and metastatic lesions.

54 ficantly higher in primary melanomas than in metastatic lesions.

55 tly inhibited the number of spontaneous lung metastatic lesions.

56 CC and may not adequately characterize small metastatic lesions.

57 tic tumors, but is dramatically increased in metastatic lesions.

58 anying normal epithelium and preinvasive and metastatic lesions.

59 y occurs only in neoplasia, most strongly in metastatic lesions.

60 s, but not from biologically late primary or metastatic lesions.

61 rculation compromised efficient outgrowth of metastatic lesions.

62 for 90% of 175 carcinomas, including 9 of 12 metastatic lesions.

63 as maintained both in the primary tumors and metastatic lesions.

64 and increased significantly to nearly 60% in metastatic lesions.

65 in 44% of primary breast cancers and 90% of metastatic lesions.

66 CXCR2 ligands, and IL-17 receptor within the metastatic lesions.

67 in ductal carcinoma in situ to nearly 50% in metastatic lesions.

68 None of the nine ras/p21+/+ mice had metastatic lesions.

69 wth of primary tumors and the development of metastatic lesions.

70 and independently according to the number of metastatic lesions.

71 n objective response with regression of bone metastatic lesions.

72 newly formed bone matrix within osteoblastic metastatic lesions.

73 idermoid cysts, cerebellar astrocytomas, and metastatic lesions.

74 n family member 3 (Wasf3) is up-regulated in metastatic lesions.

75 of a spectrum of biological virulence within metastatic lesions.

76 aromatase availability in primary tumors and metastatic lesions.

77 f potentially effective chemotherapeutics to metastatic lesions.

78 pression of HSPG2 in both primary tumors and metastatic lesions.

79 minantly associated with cancer cells in the metastatic lesions.

80 cancers, SOD2 is significantly increased in metastatic lesions.

81 ed core biopsies that corresponded to MRI of metastatic lesions.

82 tracer uptake in residual primary tumor and metastatic lesions.

83 east a macroscopic complete resection of the metastatic lesions.

84 geting potential was assessed in primary and metastatic lesions.

85 n of focal therapy-activated T cells between metastatic lesions.

86 ile maintaining the capacity to develop into metastatic lesions.

87 rs were from regional lymph node and distant metastatic lesions.

88 n also favor the rapid growth of preexisting metastatic lesions.

89 P NETs, taking into account both primary and metastatic lesions.

90 tumors, the measured mean peritumoral MD of metastatic lesions, 0.733 x 10(-3) mm(2)/sec +/- 0.061 (

91 therapy was not influenced by the number of metastatic lesions (1 vs 2-4, interaction HR = 0.98).

92 The proportion of metastatic lesions (12 of 13) with reduced expression of

93 According to biopsy analysis, only 9 of 20 metastatic lesions (45%) were pigmented with high melani

94 n in patient tumor samples was restricted to metastatic lesions (5/22; 23%) and no expression was det

95 Because of the location of metastatic lesions, a surgical approach is limited and m

96 downregulated in primary prostate tumors and metastatic lesions across multiple data sets and is by i

97 ble to deliver their therapeutic payloads to metastatic lesions after systemic administration.

98 Metastatic lesions also showed (18)F- FPPRGD2 2-fluoropr

99 cancer models, EZC3 facilitated detection of metastatic lesions although total prostate luciferase ex

100 metastatic tumor cells and aHSCs within the metastatic lesion and convert them as an in situ RLN dep

101 uniquely distinct from typical lung alveolar metastatic lesions and exhibited activation of the CD167

102 ed the expression of miR-7 and KLF4 in brain-metastatic lesions and found that these genes were signi

103 eiter et al. assess genetic diversity across metastatic lesions and identify a tight selective bottle

104 t TRAMP mice but was dramatically reduced in metastatic lesions and in androgen-independent disease.

105 solution treated group also developed severe metastatic lesions and progressive ascitic fluid buildup

106 04 and (99m)Tc-MIP-1405 identified most bone metastatic lesions and rapidly detected soft-tissue PCa

107 nsight into the etiology of both primary and metastatic lesions and rationalizations for tumor recurr

108 ic membrane antigen (PSMA) activity in small metastatic lesions and to determine the impact of these

109 ET in the detection of paraganglioma and its metastatic lesions and to evaluate whether tracer uptake

110 r cohort B (n = 15), CTT1057 PET detected 97 metastatic lesions, and 44 of 56 bone metastases detecte

111 ver, was reduced in primary prostate cancer, metastatic lesions, and androgen-independent disease.

112 ls into BALB/c mice results in tumor growth, metastatic lesions, and death.

113 l tools for noninvasive detection of tumors, metastatic lesions, and fibroses.

114 modulate the ability of tumor cells to form metastatic lesions, and host genetic polymorphism could

115 ility-surface area product were observed for metastatic lesions, and significantly higher arterial fr

116 c colon cancer in liver, liver away from the metastatic lesions, and skin from three patients with me

117 octapeptide to detect tumour xenografts and metastatic lesions, and to perform fluorescence-guided s

118 Metastatic lesions are detected with higher sensitivity

119 s of dissemination are poorly understood and metastatic lesions are genetically divergent from the ma

120 y simple model of metastasis formation where metastatic lesions are initiated at a rate which depends

121 the colonisation of disseminated cells into metastatic lesions are required.

122 Alternatively, multiple metastatic lesions are seeded from different clones pres

123 Multiple metastatic lesions are usually treated with whole-brain

124 ultures of breast cancer cells isolated from metastatic lesions as compared with cells that produced

125 ell-resembling expression profile in distant metastatic lesions as revealed by the analysis of metast

126 omas in situ, 107 invasive primaries, and 38 metastatic lesions), as well as 11 human melanoma cell l

127 ability of the cancer cell to develop into a metastatic lesion at that distant site.

128 evidence of recurrent BAC in the lungs or of metastatic lesions at any site.

129 mes of primary colorectal adenocarcinoma and metastatic lesions at both the gene and pathway levels,

130 tein originally found to be overexpressed in metastatic lesions but absent in the matched primary tum

131 cancer, SPARC immunoreactivity is highest in metastatic lesions but distinct contributions of tumoral

132 nhibition does not affect MAM recruitment to metastatic lesions but regulates a set of inflammatory r

133 at a high frequency in melanocytic nevi and metastatic lesions, but recent data have revealed much l

134 topic thyroid tumors compared with pulmonary metastatic lesions by 79% +/- 23 (standard deviation; P

135 suggest that SSeCKS suppresses formation of metastatic lesions by inhibiting VEGF expression and by

136 higher proliferation rate and displayed more metastatic lesions compared with controls.

137 pressing HP1Hsalpha in seven of nine distant metastatic lesions compared with normal mammary and prim

138 g, longer interval to metastasis, and single metastatic lesion correlated with better survival.

139 nt for measuring PD-L1 status in primary and metastatic lesions could be important for optimizing dru

140 Analysis of metastatic lesions demonstrated that concomitant loss of

141 The growth of disseminated tumor cells into metastatic lesions depends on the establishment of a fav

142 d tomography (CT) in terms of organ-specific metastatic lesion detection and radiation dose in patien

143 the leading cause of cancer-related deaths; metastatic lesions develop from disseminated cancer cell

144 ize, microenvironment or other features of a metastatic lesion dictate its behaviour or determine the

145 d treatment by early detection of primary or metastatic lesions, differentiating benign from malignan

146 Further, cells obtained from bone marrow metastatic lesions displayed self-renewal capability in

147 On the contrary, breast cancer bone metastatic lesions do select for high levels of NOG expr

148 alterations that could be masked in advanced metastatic lesions due to their inherently high genetic

149 Assessment of metastatic lesions during anti-PD-1 therapy demonstrated

150 a controlled primary tumour and one to five metastatic lesions, Eastern Cooperative Oncology Group s

151 nt tumor recurrence and the establishment of metastatic lesions, either during chemotherapy or after

152 unohistochemistry analysis in PC tissues and metastatic lesions established an association between NC

153 advanced castrate-resistant prostate cancer, metastatic lesions exhibited an increased CD14(+)/CD206(

154 showed that the prostatic tumors as well as metastatic lesions expressed high levels of MUC18, indic

155 om primary breast tumors and also from brain metastatic lesions followed by microRNA profiling analys

156 in known driver genes were present in every metastatic lesion for each patient studied.

157 scientifically, as the stochastic nature of metastatic lesion formation introduces complexity for bo

158 oliferative outbreak of dormant BC cells and metastatic lesion formation; however, SFK inhibition did

159 ed on the longitudinal measurements of liver metastatic lesions from 599 mCRC patients.

160 high-grade PanIN, 79% of primary, and 83% of metastatic lesions from human pancreatic tissue samples

161 Multiple metastatic lesions from individual patients were analyze

162 RNA from primary and metastatic lesions from patients with melanoma was hybri

163 effects, and we verified their expression in metastatic lesions from patients with melanoma.

164 aging, the heterogeneous expression of FR in metastatic lesions from the same patient, and the inabil

165 nd treatment of prostate adenocarcinoma, the metastatic lesions from this tumor are incurable.

166 tracranial neoplasms, including meningiomas, metastatic lesions, glioblastomas multiforme, and low-gr

167 Substantial regressions of metastatic lesions have been observed in up to 70% of pa

168 MUC5AC is overexpressed in both primary and metastatic lesions; however, its functional role is not

169 ction resulted in suppression of primary and metastatic lesions, i.t. replication and necrosis, vecto

170 onstrated by immunohistochemical analysis of metastatic lesions, IFN-gamma enzyme-linked immunosorben

171 icity profile and regression of at least one metastatic lesion in 12 of 30 patients.

172 east cancer and with at least one measurable metastatic lesion in the liver that was treated with 3 c

173 an tumor cells during the establishment of a metastatic lesion in zebrafish.

174 Seventy-four metastatic lesions in 10 women and 18 men (mean age, 61.

175 Results There were 242 distant metastatic lesions in 30 patients, 18 breast cancers in

176 ary adenocarcinoma of the lung with numerous metastatic lesions in both cerebral and cerebellar hemis

177 ners have increased detection of primary and metastatic lesions in both tumor types with [18F]deoxygl

178 disease settings and during the formation of metastatic lesions in cancer-bearing mice.

179 er has the potential to identify primary and metastatic lesions in different anatomic locations.

180 T-guided biopsy of (18)F-FDG-avid primary or metastatic lesions in different locations consented to p

181 ng pathways was shown to markedly reduce the metastatic lesions in established lung metastases.

182 on paraffin-embedded pancreatic tissues and metastatic lesions in liver, lungs, and lymph nodes.

183 al-like breast carcinoma that readily formed metastatic lesions in lungs of mice.

184 ion was relatively higher in prostate cancer metastatic lesions in lymph node, lung, and bone/bone ma

185 arison with the corresponding EBER1-positive metastatic lesions in lymph nodes (10 cases) and EBV-inf

186 patterns at the invasive front of pulmonary metastatic lesions in murine and human patient samples.

187 are more invasive in vitro and produce more metastatic lesions in orthotopic transplants than Coroni

188 nt of residual tumor in resection margins or metastatic lesions in patients with ccRCC.

189 ls resulted in the production of microscopic metastatic lesions in the brain parenchyma, without a de

190 Only 61% of metastatic lesions in the brain were identified at PET.

191 Whole-body optical images showed metastatic lesions in the brain, liver, and bone of B16F

192 e, growth of the primary colon tumor and its metastatic lesions in the liver and skeleton.

193 ke indices for residual primary tumor or any metastatic lesions in the liver, bone, lung, or lymph no

194 ssion of AQPs 1 and 5 was maintained even in metastatic lesions in the liver.

195 n chromosome 16 were injected, the number of metastatic lesions in the lung was significantly reduced

196 etaRIIDN-BM mice showed a virtual absence of metastatic lesions in the lung.

197 At 4 weeks after F5M2 cell inoculation, metastatic lesions in the lungs were detectable using CX

198 re was a reduction in the number and size of metastatic lesions in the lungs.

199 Treatment of metastatic lesions in the orbit and ocular adnexa is usu

200 stically reduced the incidence and growth of metastatic lesions in vitro or in vivo, respectively.

201 y induced EMT but also enabled cells to form metastatic lesions in vivo.

202 on of organ-confined tumors and emergence of metastatic lesions in young mice.

203 mean age, 54 years) with one or two painful metastatic lesions involving bone, with a score of 4 or

204 tributing to the establishment and growth of metastatic lesions is crucial for the development of nov

205 opment of quick and simple methods to detect metastatic lesions is in high demand.

206 naling in prostate cancer cells within boney metastatic lesions is not clearly understood.

207 however, deriving this information from the metastatic lesions is not feasible until after resection

208 f the somatic genetic alterations found in a metastatic lesion isolated at first relapse.

209 ocated to the cytoplasm, whereas in PDAC and metastatic lesions, its expression is significantly dimi

210 suggest that discordance between primary and metastatic lesions leads to detrimental outcome.

211 e largest lymph node (N), and of the largest metastatic lesion (M); SUVmax; SUVmean; size-incorporate

212 imal models and to the concern that multiple metastatic lesions may be more resistant to immunotherap

213 ations present in each patient's primary and metastatic lesions (mean, 75%).

214 ary site of origin for an independent set of metastatic lesions (n = 50), resected from brain, lung,

215 hat AKT is activated in both the thyroid and metastatic lesions of a mouse model of follicular thyroi

216 tly up-regulated in primary brain tumors and metastatic lesions of brain homing cancers, we show that

217 l diagnostic test for detecting recurrent or metastatic lesions of breast carcinoma.

218 or metastases or radiologically unequivocal metastatic lesions of histologically proven primary tumo

219 ional imaging modalities in the detection of metastatic lesions of SDHB-associated PGL.

220 Since metastatic lesions of solid tumors are the major cause o

221 s in normal human skin and blood compared to metastatic lesions of subjects with progressive stage IV

222 oma continues to account for the majority of metastatic lesions of the orbit and ocular adnexa.

223 essed and activated in anatomically distinct metastatic lesions of the same patient is not known.

224 is also highly expressed in both primary and metastatic lesions of TRAMP mice.

225 Growth of metastatic lesions of WT, syngeneic melanoma cells in th

226 asis is less than 6 months, and even a small metastatic lesion often causes severe neurological disab

227 y explain in part the heterogeneous fates of metastatic lesions often observed in the clinic post-the

228 curative intent, three or fewer extracranial metastatic lesions on choline positron emission tomograp

229 In two patients, obvious metastatic lesions on functional imaging were missed by

230 prior malignancy, who were asymptomatic for metastatic lesions on initial clinical examination, and

231 re, two out of the eight ras/p21-/- mice had metastatic lesions, one in its lungs, the other in its a

232 Patients had at least two metastatic lesions: one that could be safely irradiated

233 rtery of mice, K-1735 melanoma cells produce metastatic lesions only in the brain parenchyma, whereas

234 cells of B16 x K-1735 melanoma cells produce metastatic lesions only in the leptomeninges and ventric

235 f 2000 cGy or more could be delivered to the metastatic lesion or lesions, therapeutic radioiodine wa

236 imultaneous decrease and increase in size of metastatic lesions or appearance of new ones.

237 levels, both within primary (p < 0.001) and metastatic lesion (p = 0.010).

238 n both the primary tumors (P >/= 0.0198) and metastatic lesions (P >/= 0.0067), respectively, by chi(

239 In contrast to metastatic lesions, primary melanomas did not host folli

240 and bone degradation and also contributes to metastatic lesions reinitiation.

241 ably, cytoplasmic expression was elevated in metastatic lesions relative to primary tumors (P = 0.03)

242 lial-to-mesenchymal transition, and yet most metastatic lesions remain epithelial in nature.

243 umor is curable by conventional methods, but metastatic lesions remain refractile to current treatmen

244 cadherin profiles on peritoneal anchoring of metastatic lesions remains poorly understood.

245 use for resistance to treatment in 20-30% of metastatic lesions remains to be identified.

246 ability of cancer cells to establish lethal metastatic lesions requires the survival and expansion o

247 Metastatic lesions resected after vaccination showed T l

248 Finally, we found that individual metastatic lesions responded concordantly to targeted th

249 asive ductal carcinomas and their autologous metastatic lesions revealed an inverse correlation for t

250 nts of monoclonal and polyclonal primary and metastatic lesions revealed that this cooperation is ind

251 etermine the primary subclone from which the metastatic lesion(s) originated.

252 group), or standard of care plus SABR to all metastatic lesions (SABR group), using a computer-genera

253 tested using in situ hybridization on 30 pre-metastatic lesions, showing intratumoral concentration o

254 could assess HER2 status in both primary and metastatic lesions simultaneously, could be a valuable t

255 A-mutant tumor drug response and reduces the metastatic lesion size.

256 s an improvement of at least 50% in previous metastatic lesions subjectively or a change from prior d

257 ighly expressed in primary tumors but not in metastatic lesions, suggesting that ARID1A can be lost a

258 ILC patients, (18)F-FES PET/CT detected more metastatic lesions than (18)F-FDG PET/CT.

259 ression in human cancers was higher in liver metastatic lesions than in primary lesions.

260 ters and that clusters more efficiently seed metastatic lesions than single circulating tumor cells.

261 l-time primary tumor growth and formation of metastatic lesions that developed in the spleen, bowel,

262 ic MMTVneu mice spontaneously develop BC and metastatic lesions that overexpress cyclin D1 and VPAC1

263 Mean pretreatment DUR values in the metastatic lesions that responded did not differ signifi

264 Metastatic lesions that were resected after vaccination

265 es dormant D2.0R cells to form proliferative metastatic lesions through beta1-integrin signaling.

266 ta strongly support the need for biopsies of metastatic lesions to accurately determine patient progn

267 precision medicine to longitudinally sample metastatic lesions to capture the evolving constellation

268 nt enables Pfkfb3 to drive dormant BCSCs and metastatic lesions to recur.

269 ltrating leukocytes (TILs) and CD3+ cells in metastatic lesions to search for a molecular basis for t

270 The infused cells must accumulate in metastatic lesions to suppress growth; however, this pro

271 The aim of this study is to analyze cases of metastatic lesions to the gingiva compared with cases me

272 reduced formation of prostate-tumor derived metastatic lesions to the lungs in an in vivo spontaneou

273 ween 1916 and 2011 was searched for cases of metastatic lesions to the oral mucosa; only cases metast

274 For solid tumors and metastatic lesions, tumor vascularity is a critical fact

275 creased in the developing adenoma through to metastatic lesions, understanding the function of the BA

276 or burden indices of total fluoride skeletal metastatic lesion uptake (TLF10) and total volume of flu

277 active uPA in small soft-tissue and osseous metastatic lesions using a cardiac dissemination prostat

278 SUVmax for the largest metastatic lesion was the only variable independently as

279 Importantly, the development of pulmonary metastatic lesions was also reduced.

280 The expression of IL-13Ralpha2 in metastatic lesions was found to be increased compared wi

281 onal TRF2 null primary tumors, the number of metastatic lesions was similar to control cancers.

282 While dissemination of metastatic lesions was widespread in old bigenic mice we

283 ensity of prostate cancer cells to form bone metastatic lesions, we investigated whether the alphavbe

284 Nine mice with visible, palpable, or unknown metastatic lesions were entered into the protocol.

285 as, 84 primary colorectal carcinomas, and 13 metastatic lesions were evaluated immunohistochemically

286 agents (n = 33 each), whereas slightly more metastatic lesions were observed with (68)Ga-PSMA-11 in

287 Thirty-eight metastatic lesions were seen at MR imaging; 23 (61%) of

288 Emergent metastatic lesions were subjected to microarray analysis

289 ts with known independent primary tumors and metastatic lesions were used for lineage test developmen

290 CR-CSCs, including four from chemoresistant metastatic lesions, were used for in vitro studies and t

291 All metastatic lesions, when compared to the pre-treatment t

292 MP mice and was elevated in the accompanying metastatic lesions, whereas prostatic IGF-I mRNA remaine

293 efit, and to determine the maximum number of metastatic lesions wherein SABR provides a benefit.

294 d DUBs like USP9X and UBP7 in both tumor and metastatic lesions, which is further confirmed in additi

295 pful in differentiation of the origin of the metastatic lesion with known SEL features.

296 y regimens, who exhibited regression of some metastatic lesions with concomitant progression of other

297 ptors and tumor-infiltrating immune cells in metastatic lesions with or without ER mutations.

298 nts showed high tracer uptake in primary and metastatic lesions with T/M, T/B, and T/I ranging from 5

299 with a controlled primary malignancy and 1-5 metastatic lesions, with all metastases amenable to ster

300 ect detection of reporter gene expression in metastatic lesions within sentinel lymph nodes.